title: Nobori stent shows less vascular inflammation and early recovery of endothelial function compared with Cypher stent.
abstract: OBJECTIVE
  The current study sought to examine inflammation at the stented segments of Nobori (Terumo Corporation, Tokyo, Japan) and Cypher (Cordis, Miami, Florida) drug-eluting stents (DES), as well as free radical production and endothelial function of the adjacent nonstented segments in a pig coronary model.
  
  
  BACKGROUND
  Nobori is a novel DES, incorporating a biolimus A9-eluting biodegradable polymer coated only on the abluminal surface of the stent. These unique features may favorably affect inflammation and endothelial function, as compared to the currently marketed DES. Presently, pre-clinical data on direct comparison of the various generations of DES are not available.
  
  
  METHODS
  A total of 18 DES were implanted in pig coronary arteries and subsequently explanted at 1 month. Stented segments were assessed by angiography and histology. Ex vivo vasomotor function and superoxide production in segments proximal and distal to the stent were determined. The vasoconstriction, endothelial-dependent relaxation, and endothelial-independent relaxation of proximal and distal nonstented segments were measured.
  
  
  RESULTS
  Histological evaluation revealed lower inflammatory response with Nobori than with Cypher DES. There is trend for lower angiographic percentage diameter stenosis in Nobori versus Cypher groups (p = 0.054). There was increased endothelium-dependent relaxation, decreased endothelin-1-mediated contraction, and less superoxide production in the vessel segments proximal and distal to Nobori versus Cypher stents.
  
  
  CONCLUSIONS
  Our data show significantly lower inflammatory response in the stented segments, and rapid recovery of endothelial function of peristent segments in the Nobori group compared with Cypher DES group at 1 month in porcine coronary artery model.
authors.affiliation: Saint Joseph's Translational Research Institute, Atlanta, Georgia 30313, USA.
authors.forename: Lakshmana K
authors.initials: LK
authors.lastname: Pendyala
authors.forename: Daisuke
authors.initials: D
authors.lastname: Matsumoto
authors.forename: Toshiro
authors.initials: T
authors.lastname: Shinke
authors.forename: Taizo
authors.initials: T
authors.lastname: Iwasaki
authors.forename: Ryota
authors.initials: R
authors.lastname: Sugimoto
authors.forename: Dongming
authors.initials: D
authors.lastname: Hou
authors.forename: Jack P
authors.initials: JP
authors.lastname: Chen
authors.forename: Jaipal
authors.initials: J
authors.lastname: Singh
authors.forename: Spencer B
authors.initials: SB
authors.lastname: King
authors.forename: Nicolas
authors.initials: N
authors.lastname: Chronos
authors.forename: Jinsheng
authors.initials: J
authors.lastname: Li
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D000818:Animals; D002317:Cardiovascular Agents / Q000008:administration & dosage; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D003331:Coronary Vessels / Q000187:drug effects / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D054855:Drug-Eluting Stents; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D007249:Inflammation / Q000209:etiology / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D007564:Japan; D023421:Models, Animal; D011474:Prosthesis Design; D020127:Recovery of Function; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D013481:Superoxides / Q000378:metabolism; D034421:Sus scrofa; D013997:Time Factors; D014661:Vasoconstriction; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014664:Vasodilation; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D002317:Cardiovascular Agents; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D013481:Superoxides; C518022:umirolimus; D020123:Sirolimus